Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer - Reply

被引：1
|
作者：
Sabbatini, Paul
Odunsi, Kunle
机构：
[1] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol Serv, New York, NY 10021 USA
[2] Roswell Pk Canc Inst, Div Gynecol Oncol, Buffalo, NY 14263 USA
来源：
CLINICAL CANCER RESEARCH | 2007年 / 13卷 / 13期
关键词：
D O I：
10.1158/1078-0432.CCR-07-0718
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4026 / 4027
页数：2
相关论文
共 50 条
  • [21] Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Hagemann, Andrea R.
    Zighelboim, Israel
    Novetsky, Akiva Pesach
    Gao, Feng
    Massad, L. Stewart
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David Gardner
    Wright, Jason D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] A randomised Phase II study of phenoxodiol with platinum or taxane chemotherapy in chemoresistant epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer
    Goss, G.
    Quinn, M.
    Rutherford, T.
    Kelly, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 261 - 261
  • [23] Phase I study of pemetrexed (P) and pegylated liposomal doxorubicin (PLD) in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer
    Richards, D. A.
    Loesch, D.
    Vukelja, S. J.
    Wu, H. H.
    Hyman, W. J.
    Nieves, J.
    Wang, Y.
    Hu, S.
    Shonukan, O.
    Tai, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
    Berkenblit, A
    Seiden, MV
    Matulonis, UA
    Penson, RT
    Krasner, CN
    Roche, M
    Mezzetti, L
    Atkinson, T
    Cannistra, SA
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 624 - 631
  • [25] Bevacizumab Combination Therapy: A Review of its Use in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Sohita Dhillon
    BioDrugs, 2013, 27 : 375 - 392
  • [26] Bevacizumab Combination Therapy: A Review of its Use in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Dhillon, Sohita
    BIODRUGS, 2013, 27 (04) : 375 - 392
  • [27] Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer
    Herzog, Thomas J.
    Powell, Matthew A.
    Rader, Janet S.
    Gibb, Randall K.
    Lippmann, Lynne
    Coleman, Robert L.
    Mutch, David G.
    GYNECOLOGIC ONCOLOGY, 2008, 111 (03) : 467 - 473
  • [28] Phase I/II study of weekly paclitaxel with or without alisertib, an investigational aurora a Kinase inhibitor: phase I results in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal, or breast cancer
    Falchook, G.
    Goff, B.
    Kurzrock, R.
    Gray, H.
    Martin, L.
    Coleman, R.
    Xiao, H.
    Zhou, X.
    Benaim, E.
    Schilder, R.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S31 - S32
  • [29] Surgical treatment of primary ovarian fallopian tube and peritoneal cancer
    Lindemann, Kristina
    Halaska, Michael J.
    Zalewski, Kamil
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 5 - 8
  • [30] Phase I study of combination chemotherapy with irinotecan and gemcitabine for taxane/platinum resistant ovarian, fallopian tube, or primary peritoneal cancer
    Yoshino, Kiyoshi
    Kamiura, Shoji
    Ogawa, Haruki
    Tokuhira, Atsushi
    Takemura, Masahiko
    Sawada, Kenjiro
    Ueda, Yutaka
    Mabuchi, Seiji
    Fujita, Masami
    Tsutsui, Tateki
    Kimura, Tadashi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345